《大行》大摩:药明生物(02269.HK)售爱尔兰设施牺牲短期收入 但对盈利能力和资金运用正面

阿斯达克财经
Jan 07, 2025

药明生物(02269.HK) 作价5亿美元向默沙东出售爱尔兰疫苗设施,价格接近其4.8亿美元的总建设成本,公司指出,投资回报率是今次交易背后的主要考虑因素。摩根士丹利发表报告表示,由于该资产对于药明生物的投资回报率低于目标,根据药明康德管理层的说法,交易对双方而言似乎是双赢。而公司的其他爱尔兰设施的营运维持不变,稳定阶段的毛利率约为40%。关于现金收益的使用,药明康德将进一步作回购股份,并进行回报...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10